Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep;43(3):1015-1035.
doi: 10.1007/s10555-024-10183-w. Epub 2024 Mar 26.

Glioblastoma stem cell metabolism and immunity

Joseph Hawly  1 , Micaela G Murcar  2 , Alejandro Schcolnik-Cabrera  3 , Mark E Issa  4
Affiliations
Review

Glioblastoma stem cell metabolism and immunity

Joseph Hawly et al. Cancer Metastasis Rev. 2024 Sep.

Abstract

Despite enormous efforts being invested in the development of novel therapies for brain malignancies, there remains a dire need for effective treatments, particularly for pediatric glioblastomas. Their poor prognosis has been attributed to the fact that conventional therapies target tumoral cells, but not glioblastoma stem cells (GSCs). GSCs are characterized by self-renewal, tumorigenicity, poor differentiation, and resistance to therapy. These characteristics represent the fundamental tools needed to recapitulate the tumor and result in a relapse. The mechanisms by which GSCs alter metabolic cues and escape elimination by immune cells are discussed in this article, along with potential strategies to harness effector immune cells against GSCs. As cellular immunotherapy is making significant advances in a variety of cancers, leveraging this underexplored reservoir may result in significant improvements in the treatment options for brain malignancies.

Keywords: Brain tumors; Cancer metabolism; Cancer stem cells; Elimination; Equilibrium; Escape; Immunoediting; Immunotherapy; Microglia; Natural killer cells; Resistance; Self-renewal; Surveillance; T cells; Tumorigenicity.

PubMed Disclaimer

References

    1. Alvarado, A. G., Thiagarajan, P. S., Mulkearns-Hubert, E. E., Silver, D. J., Hale, J. S., Alban, T. J., … Lathia, J. D. (2017). Glioblastoma cancer stem cells evade innate immune suppression of self-renewal through reduced TLR4 expression. Cell Stem Cell, 20(4), 450–461.e4. https://doi.org/10.1016/j.stem.2016.12.001
    1. Garnier, D., Renoult, O., Alves-Guerra, M.-C., Paris, F., & Pecqueur, C. (2019). Glioblastoma stem-like cells, metabolic strategy to kill a challenging target. Frontiers in Oncology, 9, 118. https://doi.org/10.3389/fonc.2019.00118 - DOI - PubMed - PMC
    1. Esparza, R., Azad, T. D., Feroze, A. H., Mitra, S. S., & Cheshier, S. H. (2015). Glioblastoma stem cells and stem cell-targeting immunotherapies. Journal of Neuro-Oncology, 123(3), 449–457. https://doi.org/10.1007/s11060-015-1729-x - DOI - PubMed
    1. Geller, M. A., & Miller, J. S. (2011). Use of allogeneic NK cells for cancer immunotherapy. Immunotherapy, 3(12), 1445–1459. https://doi.org/10.2217/imt.11.131 - DOI - PubMed
    1. National Cancer Institute. (n.d.). Surveillance, Epidemiology, and End Results (SEER) Program Explorer Application. Retrieved April 5, 2023, from https://seer.cancer.gov/statistics-network/explorer/application.html?sit...

LinkOut - more resources